Cognition Therapeutics Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other neuro- degenerative diseases of the human brain. Toxic proteins play a crucial role in a large number of human diseases, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small-molecule drug candidates.
The societal costs of neurodegenerative diseases are enormous; Alzheimer’s disease (AD) is the most common cognitive dementia, affecting one of every ten people over age 65 and nearly 35% over age 85. This translates into more than 5.4 million AD patients in the US alone, a number expected to reach 9 million by 2030 and 16 million by 2050 as the US population ages. AD is the 6th leading cause of death in the US and is the only leading cause of death currently without a way to prevent, cure or slow the disease (of the top 10 leading causes). As many as 25 million people worldwide are afflicted with less severe memory impairment known as mild cognitive impairment (MCI), which manifests several years before an actual clinical diagnosis of AD can be made. Patients suffering in the later stages of AD require nearly full-time care; in the US alone, the economic burden of AD is estimated to be in excess of $110B annually.
Cognition’s biology and chemistry platforms have delivered first-in-class drugs that selectively block soluble Abeta oligomer- induced toxicity on synapses without affecting normal Abeta expression or function. Mechanism of action studies on these proprietary drugs have revealed a number of novel strategies to target receptors and pathways central to the pathology of Alzheimer’s disease.